Previous PostIView-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA
Next PostPalvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita